MedTrace Logo

Preoperative Block for Anterior Cervical Spine Surgery

NCT06867510 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-03-10

No results posted yet for this study

Summary

The purpose of this clinical trial study is to compare the analgesic effects of ultrasound-guided intermediate cervical plexus block Versus cervical erector spinae block in patients undergoing anterior cervical spine surgery.

* The main questions it aims to answer are:

* The primary outcome will be recording postoperative pain intensity using Numerical Rating Scale (NRS).
* The secondary outcomes will be measuring the performance time, onset of the sensory block, intraoperative fentanyl consumption, time to the first call for rescue analgesia (nalbuphine), postoperative total nalbuphine consumption, and postoperative complications such as nausea, vomiting, hypotension, and bradycardia.
* We will compare two blocks to a placebo.
* Participants will:

* undergo ultrasound-guided intermediate cervical plexus block or cervical erector spinae block or a placebo
* Be assessed for pain after 2 h, 4 h, 6 h, 12 h, and 24 h postoperatively

Conditions

  • Anesthesia, Local

Interventions

PROCEDURE

Block for Anterior Cervical Spine Surgery

The patient will be positioned supine with a slight elevation of the head and the head turned away from the blocked side. After sterilizing the skin, the ultrasound probe will be placed over the middle of the posterior border of the sternocleidomastoid muscle. The needle will be inserted in-plane while keeping the probe in a transverse position. The needle tip will be placed under the sternocleidomastoid muscle and below the superficial fascia, and then, a total volume of 15 ml of 0.25% bupivacaine will be injected bilaterally. The spread of the local anesthetic will be visualized using ultrasound guidance. The same steps will be repeated on the other side

DRUG

Saline (NaCl 0,9 %) (placebo)

Total volume of 15 ml of saline 0.9% will be injected subcutaneous bilaterally

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-04-01
Completion
2026-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867510 on ClinicalTrials.gov